|
注册号: Registration number: |
ChiCTR2300067499 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-03 00:43:16 |
|
注册时间: Date of Registration: |
2023-01-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
人工智能在肠镜检查时辅助肠道准备的效益 |
|
Public title: |
Clinical Analysis Between Artificial Intelligence (AI) Assisted evaluation and Conventional Booklet Education Effect for Bowel Preparation Before Colonoscopy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
人工智能在肠镜检查时辅助肠道准备的效益 |
|
Scientific title: |
Clinical Analysis Between Artificial Intelligence (AI) Assisted evaluation and Conventional Booklet Education Effect for Bowel Preparation Before Colonoscopy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吕元博 |
研究负责人: |
黄咏宁 |
|
Applicant: |
Yangbo Lu |
Study leader: |
Yungning Huang |
|
申请注册联系人电话: Applicant telephone: |
+86 153 5988 5362 |
研究负责人电话:
Study leader's |
+86 153 5988 5009 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
bentleylu@gmail.com |
研究负责人电子邮件: Study leader's E-mail: |
ning0219@gmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省厦门市海沧区霞飞路123号 |
研究负责人通讯地址: |
福建省厦门市海沧区霞飞路123号 |
|
Applicant address: |
123 Xiafei Road, Haicang District, Xiamen, Fujian |
Study leader's address: |
123 Xiafei Road, Haicang District, Xiamen, Fujian |
|
申请注册联系人邮政编码: Applicant postcode: |
361000 |
研究负责人邮政编码: Study leader's postcode: |
361000 |
|
申请人所在单位: |
厦门长庚医院 |
||
|
Applicant's institution: |
Xiamen Chang Gung Hospital |
||
|
研究负责人所在单位: |
厦门长庚医院 |
||
|
Affiliation of the Leader: |
Xiamen Chang Gung Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XMCGIRB2022074 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
厦门长庚医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Xiamen Chang Gung Hospital Institutional Review Board |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-10-24 00:00:00 | ||
|
伦理委员会联系人: |
陈丽娜 |
||
|
Contact Name of the ethic committee: |
Li-Na Chen |
||
|
伦理委员会联系地址: |
福建省厦门市海沧区霞飞路123号 |
||
|
Contact Address of the ethic committee: |
123 Xiafei Road, Haicang District, Xiamen, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 592 6202834 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
厦门长庚医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiamen Chang Gung Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市海沧区霞飞路123号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
123 Xiafei Road, Haicang District, Xiamen, Fujian |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
厦门长庚医院科研基金CMRPG |
||||||||||||||||||||||
|
Source(s) of funding: |
Xiamen Chang Gung Hospital CMRPG |
||||||||||||||||||||||
|
研究疾病: |
结肠疾病 |
||||||||||||||||||||||
|
Target disease: |
colon disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.主要目的 主要评估指标:所有入组AI与常规组进行平均饮用剂量的比较,而且下降剂量须达0.5L才算有达临床意义 2.次要目的 (1) BBPS>=7分的AI组才视为分析群,与常规组进行比较,平均用药剂量相较常规组可减量多少? (2) BBPS≥8分的AI组才视为分析群,与常规组进行比较,平均用药剂量相较常规组可减量多少? (3) BBPS或其他指标(ex. 病人满意度、不良反应),比较AI组是否比常规组更好? (4) 比较AI组与常规组的其他安全性指标(ex. 病人满意度、不良反应) |
||||||||||||||||||||||
|
Objectives of Study: |
1. Main Purpose Main evaluation indicator: Compare the average drinking dose of all enrolled AI with the conventional group, and the reduced dose must reach 0.5L to achieve clinical significance 2. Secondary Purpose (1) The AI group with BBPS>=7 points is considered as the analysis group. Compared with the conventional group, how much can the average medication dose be reduced compared to the conventional group? (2) The AI group with BBPS ≥ 8 points is considered as the analysis group. Compared with the conventional group, how much can the average medication dose be reduced compared to the conventional group? (3) Is the AI group better than the conventional group in terms of BBPS or other indicators (ex. patient satisfaction, adverse reactions)? (4) Compare other safety indicators (ex. patient satisfaction, adverse reactions) between the AI group and the conventional group |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)肠镜检查禁忌症者; (2)怀孕; (3)因任何原因不能配合检查之受检者; (4)受檢者拒絕。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Contraindication of colonoscopy; (2) Pregnancy; (3) Subjects who are unable to cooperate with the examination for any reason; (4) The subject refused. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-01-01 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
组患者借由电脑软体,借由扫描QR code时,进行简单随机分布入组于干预组(人工智能辅助)及对照组(传统肠道准备) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Enrolled patients were all equally randomized into either the AI assisted evaluation subgroup or the conventional education with self-evaluated group with simple randomization by computer software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
当研究结束时,我们将可分享数据。可使用bentleylu@yahoo.com索取资料。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
we will share all data after the study finished, and we share IPD by email box. bentleylu@yahoo.com |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
此研究采用Case record form进行所有病患资料的纪录及管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
we will use the Case Report Form(CRF) to collect data and record managements. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |